Research · Sep 3, 2026
[IMCR] Immunovant Thesis 2026: IMVT-1402 Albumin-Neutral FcRn Advances Toward MG Pivotal Data
Immunovant FY2025 (ended Mar 2025): cash ~$560M funding Phase 3 programs. IMVT-1402 (albumin-neutral FcRn inhibitor) in ASCEND-MG Phase 3 and ASCEND-CIDP Phase 2/3 — the lead asset with differentiated safety profile vs approved argenx VYVGART. Batoclimab in VALOR Phase 3 (thyroid eye disease, data FY2026 H1) as potential first NDA-enabling dataset. FY2026 thesis: VALOR TED data creates first approval path; IMVT-1402 MG/CIDP Phase 3 data (FY2027) determines whether the albumin-neutral FcRn positioning justifies $8-12B valuation vs current $2-4B; Roivant majority ownership provides capital backstop through data readouts.